Pre-TACE CK-MB/CK Ratio as an Independent Prognostic Biomarker in Advanced Hepatocellular Carcinoma Authors: Weiguo Lu, Ying Lu, Yang Wang Published: 2026 ABSTRACT PurposePrimary liver cancer is a prevalent malignancy with a poor prognosis globally. Patients with advanced disease often undergo transarterial chemoembolization (TACE), yet simple and effective prognostic biomarkers are lacking. This study aimed to investigate the prognostic value of the serum creatine kinase isoenzyme MB to total creatine kinase (CK-MB/CK) ratio in patients with advanced primary liver cancer receiving TACE.Patients and MethodsA single-center retrospective cohort study was conducted, enrolling 158 patients between January 2021 and September 2024. Based on a CK-MB/CK ratio cutoff of 1, patients were categorized into an abnormal group (n=52) and a normal group (n=106). Comparative analysis of baseline characteristics, Kaplan-Meier survival analysis, and Cox proportional hazards regression modeling were performed to assess the relationship between the CK-MB/CK ratio and overall survival (OS).ResultsPatients in the abnormal group exhibited lower body mass index (BMI), lower rates of previous hepatectomy, higher levels of tumor markers (including AFP and CEA), and poorer liver function indices compared to the normal group. Kaplan-Meier analysis revealed a significantly shorter OS in the abnormal group (median OS: 15.0 months vs 32.5 months, log-rank P < 0.001). Multivariate Cox regression analysis confirmed that an elevated CK-MB/CK ratio was an independent risk factor for OS, with a hazard ratio of 3.895 (95% confidence interval: 1.946–7.79).ConclusionThis retrospective single-center study suggests that a CK-MB/CK ratio >1 may serve as an independent and easily accessible marker of poor prognosis in patients with advanced liver cancer undergoing TACE. Further validation in larger cohorts is needed. This marker is cost-effective and readily available in routine clinical practice, showing potential for risk stratification. When combined with D-dimer, it may provide a practical tool for clinical prognostic stratification. Introduction Primary liver cancer is a highly prevalent malignancy globally, with approximately 906,000 new cases and 830,000 deaths annually, ranking as the sixth most common cancer and the third leading cause of cancer death worldwide.1 In China, the burden is particularly heavy, accounting for nearly half of the global annual incidence and mortality cases, and has become the second leading cause of cancer death in the country.2 Hepatocellular carcinoma (HCC) is its predominant pathological type. Due to its insidious early symptoms, most patients are diagnosed at an intermediate to advanced stage, missing the opportunity for curative resection.3 For advanced HCC, transarterial chemoembolization (TACE) is a widely used locoregional therapy. However, its efficacy is heterogeneous; a substantial proportion of patients develop TACE resistance, hepatic decompensation, or related complications, leading to poor outcomes.4–6 Despite extensive research on prognostic biomarkers in TACE-treated HCC—including inflammatory indices, nutritional scores, and combination nomograms—no single blood-based marker has achieved sufficient accuracy for routine clinical use, highlighting the ongoing need for novel, readily available biomarkers.7,8 Currently, commonly used prognostic indicators for TACE include serum alpha-fetoprotein (AFP), liver function scores (eg, Child-Pugh), and imaging features (eg, tumor burden, vascular invasion). However, these markers have limitations: AFP lacks sensitivity and specificity, liver function scores are confounded by underlying cirrhosis, and imaging assessments are subjective, failing to capture the tumor’s biological aggressiveness. Therefore, there is a pressing clinical need for easily accessible biomarkers to identify, prior to or early after TACE, those patients at high risk of rapid progression or poor survival, which is crucial for implementing individualized management strategies. Creatine kinase (CK) is a key enzyme regulating cellular energy metabolism, and its isoenzyme CK-MB has traditionally been regarded as a specific marker for myocardial injury.9 Nevertheless, clinical observations have frequently revealed an abnormal phenomenon where CK-MB activity exceeds total CK (ie, CK-MB/CK ratio >1.0) in cancer patients without cardiac disease. Studies have confirmed a significant association between this abnormal CK-MB/CK ratio and malignant tumors.10 An analysis of 846 patients with a ratio >1.0 showed that 40.1% were ultimately diagnosed with malignancy, most commonly colorectal cancer, lung cancer, and liver cancer.11 Furthermore, an elevated ratio was significantly correlated with advanced tumor stage and the presence of liver metastases, suggesting it may reflect aggressive tumor biology. In colorectal cancer, an abnormal postoperative CK-MB/CK ratio has been established as an independent risk factor for predicting liver metastasis and poor prognosis.12 In HCC, although direct evidence remains limited, several lines of indirect evidence support a potential link: first, rapid tumor growth and metabolic reprogramming in HCC can lead to muscle wasting and altered CK isoenzyme profiles; second, mitochondrial dysfunction in tumor cells—commonly observed in HCC and associated with disease progression—may contribute to abnormal CK-MB expression and release;13 and third, chronic hepatic inflammation and progressive liver dysfunction in advanced HCC can induce systemic metabolic alterations affecting CK metabolism.14 Collectively, this evidence positions the CK-MB/CK ratio as a potential tumor-related indicator beyond its conventional cardiac role. Although the precise mechanisms in HCC remain speculative, the abnormal ratio may be linked to aberrant mitochondrial metabolism, high tumor burden, or subclinical liver injury associated with disease progression.15,16 These potential biological mechanisms collectively underscore the rationale for using the ratio as a prognostic marker, providing a stronger logical foundation for our study findings. Notably, while the prognostic value of CK-MB/CK ratio has been reported in several other malignancies, its role in HCC, particularly in TACE-treated advanced disease, has not been systematically investigated to date. This represents a critical gap in the literature, given the unique metabolic and inflammatory milieu of advanced HCC and the widespread clinical use of TACE. However, the prognostic value of this ratio in primary liver cancer, particularly in the specific and challenging cohort of patients with advanced disease receiving TACE, remains underexplored. Given the ease of obtaining this ratio from routine blood tests, investigating its utility could address the aforementioned need for practical prognostic tools. We hypothesized that an elevated pre-TACE CK-MB/CK ratio is independently associated with poorer overall survival in patients with advanced HCC, and that this ratio provides incremental prognostic value beyond conventional clinicopathological factors. Consequently, this study aimed to systematically evaluate whether the pre-TACE CK-MB/CK ratio serves as an independent prognostic biomarker for overall survival in patients with advanced HCC undergoing TACE. We further sought to explore its relationship with clinicopathological features and its potential for risk stratification, hoping to provide a new reference for therapeutic decision-making in this population. Materials and Methods Patients The study population comprised patients with primary liver cancer who were admitted to The First Affiliated Hospital of Guangzhou University of Chinese Medicine between January 2021 and September 2024. The inclusion and exclusion criteria were as follows: Inclusion criteria: (1) Patients with a histopathologically confirmed diagnosis of primary liver cancer; (2) Patients classified as stage III–IV according to the China Liver Cancer Staging (CNLC) system and who received transarterial chemoembolization (TACE) treatment after admission; (3) Patients who had received at least one conventional treatment regimen; (4) Patients with available post-treatment follow-up data; (5) Patients with available serum CK-MB and total CK measurements prior to TACE treatment. Exclusion criteria: (1) Patients with a history of other malignancies; (2) Patients with unknown pathological stage or lacking CNLC staging data; (3) Patients confirmed to have secondary hepatic malignancies; (4) Patients with CNLC stage I–II disease; (5) Patients with myocardial injury from various causes, including cardiovascular complications, COVID-19 infection, myocardial injury after non-cardiac surgery, etc, as determined by clinical manifestations and laboratory evidence such as chest pain, electrocardiogram (ECG) findings, cardiac troponin, myoglobin, and brain natriuretic peptide; (6) Patients with incomplete data. All consecutive patients meeting the above inclusion and exclusion criteria during the study period were enrolled to minimize selection bias. Finally, a total of 158 patients were included in this retrospective study (Figure 1). We extracted necessary information from the medical records, including patient demographics, clinical data, laboratory results, histological findings, follow-up data, time to local or distant recurrence, short- and long-term outcomes, and survival rates.Figure 1Flowchart of patient selection. A total of 472 patients with stage III–IV advanced hepatocellular carcinoma (HCC) were initially screened. Of these, 94 patients with a history of other malignancies were excluded, leaving 378 patients. Subsequently, 201 patients with incomplete data were excluded, including 101 with missing survival follow-up, 56 with missing key laboratory tests (liver function, coagulation, and tumor markers), and 44 with missing clinical baseline data, leaving 177 patients. Finally, 19 patients with myocardial injury due to various causes were excluded, including 6 with cardiovascular complications, 10 with COVID-19 infection, and 3 with myocardial injury after non-cardiac surgery. A total of 158 patients were ultimately enrolled and divided into the normal group (CK-MB/CK ≤1, n=106) and the abnormal group (CK-MB/CK >1, n=52).Flowchart of patient selection for hepatocellular carcinoma study, showing exclusions and group division.The flowchart illustrates the selection process for patients with stage III-IV advanced hepatocellular carcinoma. Initially, 472 patients were screened. Ninety-four patients with a history of other malignancies were excluded, leaving 378 patients. Next, 201 patients with incomplete data were excluded, including 101 with missing survival follow-up, 56 with missing key laboratory tests and 44 with missing clinical baseline data, resulting in 177 patients. Subsequently, 19 patients with myocardial injury were excluded, including 6 with cardiovascular complications, 10 with COVID-19 infection and 3 with myocardial injury after non-cardiac surgery, leaving 158 patients. These were divided into the normal group with CK-MB/CK less than or equal to 1, consisting of 106 patients and the abnormal group with CK-MB/CK greater than 1, consisting of 52 patients.Abbreviations: HCC, hepatocellular carcinoma; CK-MB, creatine kinase isoenzyme MB; TACE, transarterial chemoembolization. Flowchart of patient selection. A total of 472 patients with stage III–IV advanced hepatocellular carcinoma (HCC) were initially screened. Of these, 94 patients with a history of other malignancies were excluded, leaving 378 patients. Subsequently, 201 patients with incomplete data were excluded, including 101 with missing survival follow-up, 56 with missing key laboratory tests (liver function, coagulation, and tumor markers), and 44 with missing clinical baseline data, leaving 177 patients. Finally, 19 patients with myocardial injury due to various causes were excluded, including 6 with cardiovascular complications, 10 with COVID-19 infection, and 3 with myocardial injury after non-cardiac surgery. A total of 158 patients were ultimately enrolled and divided into the normal group (CK-MB/CK ≤1, n=106) and the abnormal group (CK-MB/CK >1, n=52). Based on the CK-MB and CK test results, patients were divided into two groups: the abnormal group (CK-MB > CK, ie, CK-MB/CK > 1) and the normal group (CK-MB ≤ CK, ie, CK-MB/CK ≤ 1). A cutoff value of 1 was chosen based on the upper limit of the normal clinical reference range, which is widely used in laboratory practice and facilitates direct clinical translation. The study was approved by the Ethics Committee of The First Affiliated Hospital of Guangzhou University of Chinese Medicine (K-2023-135) and was conducted in accordance with the Declaration of Helsinki. Due to the retrospective nature of the research, the Ethics Committee waived the requirement for informed consent. Patient data confidentiality was strictly maintained throughout the study. TACE Treatment Protocol All TACE procedures were performed by experienced interventional radiologists following standardized protocols. Briefly, after femoral artery puncture and selective catheterization of the hepatic artery, chemotherapeutic agents (epirubicin 30–50 mg) were infused, followed by embolization with lipiodol (5–20 mL) and gelatin sponge particles. Treatment cycles were typically repeated every 4–6 weeks, with the exact interval determined by tumor response assessment and liver function evaluation. All operators followed the same standardized procedural guidelines to ensure consistency across cases. Data Collection Serum samples were collected from patients within 24 hours prior to the first TACE procedure. The collected laboratory data included: 1) Complete blood count parameters, such as hemoglobin (Hb), white blood cell count (WBC), neutrophil count (NEUT), lymphocyte count (LYM), and platelet count (PLT); 2) Tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 15–3 (CA15-3), and carbohydrate antigen 19–9 (CA19-9); 3) Biochemical indicators of liver function and reserve (eg, ALT, AST, ALB, TBIL) and coagulation parameters (eg, PT, APTT); 4) Liver function classification assessed by the Child-Pugh scoring system; 5) The activity levels of creatine kinase isoenzyme MB (CK-MB) and total creatine kinase (CK), from which the CK-MB/CK ratio was calculated for each patient. Complete blood count analysis was performed using a Mindray CN6800-plus automated hematology analyzer (Shenzhen, China). Tumor markers, CK-MB, CK, and liver function biochemical indicators were measured using the Roche Cobas 601/701 automated immunoassay and biochemistry system. For CK-MB/CK measurements, routine internal quality control was performed using commercial control materials at two concentration levels, with intra- and inter-assay coefficients of variation consistently below 5%. The instruments were calibrated according to the manufacturer’s recommended schedule to ensure assay reproducibility. Additionally, baseline demographic and clinical characteristics were extracted from the hospital’s electronic medical record system. These included gender, age, body mass index (BMI), date of liver cancer diagnosis, overall survival, history of partial hepatectomy, and tumor stage according to the China Liver Cancer Staging (CNLC) system. Statistical Analysis Statistical analyses were performed using SPSS software (version 25.0; IBM Corp). Continuous variables are presented as mean ± standard deviation if normally distributed, or as median (interquartile range) if non-normally distributed. For comparisons between two groups, the Student’s t-test was used for normally distributed data, and the Mann–Whitney U-test was applied for non-normally distributed data. A two-tailed P-value of <0.05 was considered statistically significant. Categorical variables are expressed as frequency and percentage and were compared using the Chi-square test or Fisher’s exact test, as appropriate. Univariate and multivariate Cox proportional hazards regression models were employed to identify independent risk factors affecting the prognosis and survival time of patients with primary liver cancer. Prior to multivariate analysis, multicollinearity among covariates was assessed using the variance inflation factor (VIF), with all VIF values <5 indicating no significant multicollinearity. The proportional hazards assumption was verified using Schoenfeld residuals, with no significant violations detected. Overall survival differences were assessed using the Kaplan-Meier method, and group comparisons were performed with the Log rank test. The sample size was determined based on the rule of at least 10 events per predictor variable for the Cox regression model, which, with 7 variables ultimately included, required a minimum of 70 events. The final sample of 158 patients with 52 events (death) exceeded this threshold. A post-hoc power analysis indicated that the study had >80% power to detect the observed hazard ratio of 3.9 at a significance level of 0.05. The median follow-up time was calculated using the reverse Kaplan-Meier method and will be reported in the Results section. Follow-up completeness was assessed as the proportion of patients with known survival status at the end of the study period. For laboratory variables with missing data, complete-case analysis was used, ie, cases with missing values for a specific variable were excluded from the analysis involving that variable. For subgroup analyses involving D-dimer, only patients with available D-dimer data (n = 115) were included. Results Significant Differences Between the Abnormal and Normal CK-MB/CK Ratio Groups As shown in Table 1, this study enrolled 158 patients, comprising 106 in the normal group (CK-MB/CK ratio ≤1) and 52 in the abnormal group (CK-MB/CK ratio >1). Analysis of baseline characteristics revealed that patients in the abnormal group had a significantly shorter survival time and a significantly lower body mass index (BMI) compared to those in the normal group. The proportion of patients with a history of hepatectomy was also significantly lower in the abnormal group. Additionally, the abnormal group had a higher proportion of Child-Pugh C class (25.0% vs 13.2%), although the difference did not reach statistical significance (P = 0.110).Table 1Comparison of Baseline Characteristics Between Patients with Normal and Abnormal CK-MB/CK RatiosVariablesNormal Group(CK-MB/CK ≤1, n=106)Abnormal Group(CK-MB/CK >1, n=52)P valueDemographicsAge (years)58.69 ± 11.1157.44 ± 12.120.521Male gender, n (%)96 (90.6%)41 (78.8%)0.041BMI (kg/m2)20.66 (18.37, 23.44)18.71 (17.60, 19.78)<0.001Clinical characteristicsSurvival time (months)32.5 (20.0, 46.8)15.0 (11.0, 22.3)<0.001History of hepatitis B, n (%)60 (56.6%)19 (36.5%)0.018Partial hepatectomy, n (%)42 (39.6%)10 (19.2%)0.010History of targeted therapy, n (%)82 (77.4%)34 (65.4%)0.109Immunotherapy, n (%)80 (75.5%)32 (61.5%)0.070CNLC stage, n (%)0.666IIIa29 (27.4%)11 (21.2%)IIIb62 (58.5%)32 (61.5%)IV15 (14.1%)9 (17.3%)Child-Pugh classification, n (%)0.110A37 (34.9%)12 (23.1%)B55 (51.9%)27 (51.9%)C14 (13.2%)13 (25.0%)Tumor markersAFP (ng/mL)162.8 (6.0, 8137)1350.5 (20.9, 27,160)0.091CEA (ng/mL)3.12 (2.05, 4.88)4.67 (2.59, 9.29)0.015CA125 (U/mL)32.65 (13.66, 146.20)103.67 (42.81, 176.75)0.001CA15-3 (U/mL)15.13 (10.49, 23.28)24.48 (15.10, 39.57)<0.001CA19-9 (U/mL)29.83 (13.12, 73.09)72.36 (29.66, 277.47)<0.001Liver function testsALP (U/L)135 (83.5, 234)232.5 (168.8, 408.3)0.002GGT (U/L)112 (53.25, 236.25)214 (160.75, 468.75)<0.001TP (g/L)64.63 ± 9.8866.22 ± 7.790.315ALB (g/L)33.87 ± 6.8331.32 ± 4.840.008ALT (U/L)30.5 (20, 60.5)42.5 (29, 93.8)0.006AST (U/L)51.5 (33.3, 119)120.5 (73.5, 211)<0.001TBIL (μmol/L)16.45 (8.33, 50.58)21.80 (14.05, 76.60)0.008DBIL (μmol/L)6.85 (2.73, 29.98)11.00 (6.30, 46.10)0.003Coagulation testsAPTT (s)29.8 (26.6, 37.9)32.7 (28.1, 38.1)0.182PT (s)12.1 (11.3, 13.7)12.6 (11.6, 14.5)0.273PT-INR1.01 (0.94, 1.18)1.05 (0.97, 1.22)0.225D-dimer (mg/L)1.65 (0.74, 5.55)5.82 (2.51, 9.00)<0.001Hematology and other parametersHemoglobin (g/L)113.17 ± 31.50110.71 ± 26.090.605WBC (×109/L)5.69 (4.42, 8.41)6.86 (5.34, 10.51)0.055Platelet (×109/L)141 (88, 194)139 (85, 250)0.504Neutrophil (×109/L)4.05 (2.64, 6.33)5.33 (3.90, 8.37)0.032Lymphocyte (×109/L)1.14 (0.71, 1.49)0.90 (0.73, 1.21)0.033LDH (U/L)252 (205, 327)470 (284, 987)<0.001ADA (U/L)15 (12, 18)19 (15, 26)0.005Uric acid (μmol/L)335 (284, 397)288 (244, 437)0.418Creatinine (μmol/L)65 (56, 76)65 (49, 78)0.588Urea (mmol/L)5.25 (3.65, 6.97)4.74 (4.12, 8.37)0.681Notes: All laboratory parameters were measured from pre-TACE peripheral blood samples. Categorical variables are presented as n (%), continuous variables as mean ± SD or median (IQR). P values were calculated using the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous variables.Abbreviations: BMI, body mass index; CNLC, China Liver Cancer Staging; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TP, total protein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; APTT, activated partial thromboplastin time; PT, prothrombin time; INR, international normalized ratio; WBC, white blood cell; LDH, lactate dehydrogenase; ADA, adenosine deaminase; CK-MB, creatine kinase isoenzyme MB. Table 1Comparison of Baseline Characteristics Between Patients with Normal and Abnormal CK-MB/CK RatiosVariablesNormal Group(CK-MB/CK ≤1, n=106)Abnormal Group(CK-MB/CK >1, n=52)P valueDemographicsAge (years)58.69 ± 11.1157.44 ± 12.120.521Male gender, n (%)96 (90.6%)41 (78.8%)0.041BMI (kg/m2)20.66 (18.37, 23.44)18.71 (17.60, 19.78)<0.001Clinical characteristicsSurvival time (months)32.5 (20.0, 46.8)15.0 (11.0, 22.3)<0.001History of hepatitis B, n (%)60 (56.6%)19 (36.5%)0.018Partial hepatectomy, n (%)42 (39.6%)10 (19.2%)0.010History of targeted therapy, n (%)82 (77.4%)34 (65.4%)0.109Immunotherapy, n (%)80 (75.5%)32 (61.5%)0.070CNLC stage, n (%)0.666IIIa29 (27.4%)11 (21.2%)IIIb62 (58.5%)32 (61.5%)IV15 (14.1%)9 (17.3%)Child-Pugh classification, n (%)0.110A37 (34.9%)12 (23.1%)B55 (51.9%)27 (51.9%)C14 (13.2%)13 (25.0%)Tumor markersAFP (ng/mL)162.8 (6.0, 8137)1350.5 (20.9, 27,160)0.091CEA (ng/mL)3.12 (2.05, 4.88)4.67 (2.59, 9.29)0.015CA125 (U/mL)32.65 (13.66, 146.20)103.67 (42.81, 176.75)0.001CA15-3 (U/mL)15.13 (10.49, 23.28)24.48 (15.10, 39.57)<0.001CA19-9 (U/mL)29.83 (13.12, 73.09)72.36 (29.66, 277.47)<0.001Liver function testsALP (U/L)135 (83.5, 234)232.5 (168.8, 408.3)0.002GGT (U/L)112 (53.25, 236.25)214 (160.75, 468.75)<0.001TP (g/L)64.63 ± 9.8866.22 ± 7.790.315ALB (g/L)33.87 ± 6.8331.32 ± 4.840.008ALT (U/L)30.5 (20, 60.5)42.5 (29, 93.8)0.006AST (U/L)51.5 (33.3, 119)120.5 (73.5, 211)<0.001TBIL (μmol/L)16.45 (8.33, 50.58)21.80 (14.05, 76.60)0.008DBIL (μmol/L)6.85 (2.73, 29.98)11.00 (6.30, 46.10)0.003Coagulation testsAPTT (s)29.8 (26.6, 37.9)32.7 (28.1, 38.1)0.182PT (s)12.1 (11.3, 13.7)12.6 (11.6, 14.5)0.273PT-INR1.01 (0.94, 1.18)1.05 (0.97, 1.22)0.225D-dimer (mg/L)1.65 (0.74, 5.55)5.82 (2.51, 9.00)<0.001Hematology and other parametersHemoglobin (g/L)113.17 ± 31.50110.71 ± 26.090.605WBC (×109/L)5.69 (4.42, 8.41)6.86 (5.34, 10.51)0.055Platelet (×109/L)141 (88, 194)139 (85, 250)0.504Neutrophil (×109/L)4.05 (2.64, 6.33)5.33 (3.90, 8.37)0.032Lymphocyte (×109/L)1.14 (0.71, 1.49)0.90 (0.73, 1.21)0.033LDH (U/L)252 (205, 327)470 (284, 987)<0.001ADA (U/L)15 (12, 18)19 (15, 26)0.005Uric acid (μmol/L)335 (284, 397)288 (244, 437)0.418Creatinine (μmol/L)65 (56, 76)65 (49, 78)0.588Urea (mmol/L)5.25 (3.65, 6.97)4.74 (4.12, 8.37)0.681Notes: All laboratory parameters were measured from pre-TACE peripheral blood samples. Categorical variables are presented as n (%), continuous variables as mean ± SD or median (IQR). P values were calculated using the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous variables.Abbreviations: BMI, body mass index; CNLC, China Liver Cancer Staging; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TP, total protein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; APTT, activated partial thromboplastin time; PT, prothrombin time; INR, international normalized ratio; WBC, white blood cell; LDH, lactate dehydrogenase; ADA, adenosine deaminase; CK-MB, creatine kinase isoenzyme MB. Comparison of Baseline Characteristics Between Patients with Normal and Abnormal CK-MB/CK Ratios Notes: All laboratory parameters were measured from pre-TACE peripheral blood samples. Categorical variables are presented as n (%), continuous variables as mean ± SD or median (IQR). P values were calculated using the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous variables. Abbreviations: BMI, body mass index; CNLC, China Liver Cancer Staging; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TP, total protein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; APTT, activated partial thromboplastin time; PT, prothrombin time; INR, international normalized ratio; WBC, white blood cell; LDH, lactate dehydrogenase; ADA, adenosine deaminase; CK-MB, creatine kinase isoenzyme MB. Regarding laboratory parameters, the abnormal group exhibited a significantly higher neutrophil percentage and significantly elevated levels of tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 15–3 (CA15-3), carbohydrate antigen 125 (CA125), and carbohydrate antigen 19–9 (CA19-9). Liver function indices—alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), albumin (ALB, which was lower in the abnormal group), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL)—showed significant differences between groups, indicating more severely impaired liver function in the abnormal group. Additionally, D-dimer levels were significantly elevated in the abnormal group. Collectively, these laboratory findings suggested a significantly worse prognosis for patients in the abnormal group. Markedly Shortened Survival Time in the Abnormal CK-MB/CK Ratio Group In Figure 2A, correlation analysis was performed to explore the relationships between various indicators and the CK-MB/CK ratio. Detailed results, including Spearman correlation coefficients and exact P-values for all variables, are provided in Supplementary Table 1. The results showed that ALP, lactate dehydrogenase (LDH), D-dimer, and the tumor marker CA19-9 were positively correlated with the CK-MB/CK ratio (r = −0.562, P < 0.001). Notably, overall survival was negatively correlated with the CK-MB/CK ratio, with a strong correlation coefficient and a significant P-value, suggesting that an elevated CK-MB/CK ratio may predict a poorer prognosis. Furthermore, as illustrated in Figure 2B, Kaplan-Meier survival analysis demonstrated a significantly lower survival rate in the abnormal group compared to the normal group (log-rank P < 0.001). The median overall survival was 32.5 months (95% CI: 26.0–39.0 months) in the normal group and 15.0 months (95% CI: 12.0–18.0 months) in the abnormal group. The 1-year, 2-year, and 3-year survival rates were 94.3% vs 67.3%, 62.3% vs 17.3%, and 40.6% vs 3.8%, respectively.Figure 2CK-MB/CK ratio correlates with adverse parameters and predicts poor survival in advanced HCC. (A)Spearman correlation analysis between CK-MB/CK ratio and clinicopathological parameters (n = 158). Dot color represents P value, and dot size represents absolute correlation coefficient (|r|). ALP, LDH, D-dimer, GGT, AST, CA19-9, CA15-3, and CA125 were positively correlated with CK-MB/CK ratio, while overall survival was negatively correlated (r = −0.56, P < 0.001). Detailed correlation coefficients and exact P-values for all variables are provided in Supplementary Table 1. Abnormal: >1, n = 52). Log rank test showed significantly poorer survival in the abnormal group (P < 0.001; HR = 3.895, 95% CI: 1.946–7.790). The median OS was 32.5 months (95% CI: 26.0–39.0) in the normal group and 15.0 months (95% CI: 12.0–18.0) in the abnormal group. Tick marks indicate censored observations. (B) Kaplan-Meier survival curves stratified by CK-MB/CK ratio (Normal: ≤1, n = 106.A bubble correlation plot and a Kaplan Meier survival curve comparing normal and abnormal groups.Image A displays a bubble correlation plot with variables on the y-axis (ALP, LDH, D dimer, etc.) and correlation values on the x-axis ranging from -0.6 to 0.3. Correlation values include ALP 0.35, LDH 0.34, down to Survival time -0.56. Legends indicate P values (0.04 to 0.01) and absolute correlation values (0.2 to 0.5). Image B shows a Kaplan-Meier survival plot with Normal and Abnormal curves. The x-axis is Survival Time (Months) from 0 to 90 and the y-axis is Survival Probability from 0.00 to 1.00. The Normal curve drops from 1.00 at 0 months to 0.15 at 90 months, with censor marks from 55 to 90 months. The Abnormal curve falls from 1.00 at 0 months to 0.00 at 40 months, with a censor mark near 55 months. Log rank P is less than 0.001. Numbers below the plot: Normal 106, 66, 22, 6; Abnormal 52, 9, 1, 0.Abbreviations: CK-MB, creatine kinase isoenzyme MB; HCC, hepatocellular carcinoma; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; HR, hazard ratio; CI, confidence interval. CK-MB/CK ratio correlates with adverse parameters and predicts poor survival in advanced HCC. (A)Spearman correlation analysis between CK-MB/CK ratio and clinicopathological parameters (n = 158). Dot color represents P value, and dot size represents absolute correlation coefficient (|r|). ALP, LDH, D-dimer, GGT, AST, CA19-9, CA15-3, and CA125 were positively correlated with CK-MB/CK ratio, while overall survival was negatively correlated (r = −0.56, P < 0.001). Detailed correlation coefficients and exact P-values for all variables are provided in Supplementary Table 1. Abnormal: >1, n = 52). Log rank test showed significantly poorer survival in the abnormal group (P < 0.001; HR = 3.895, 95% CI: 1.946–7.790). The median OS was 32.5 months (95% CI: 26.0–39.0) in the normal group and 15.0 months (95% CI: 12.0–18.0) in the abnormal group. Tick marks indicate censored observations. (B) Kaplan-Meier survival curves stratified by CK-MB/CK ratio (Normal: ≤1, n = 106. The CK-MB/CK Ratio Serves as an Independent Prognostic Predictor in Patients with Advanced Liver Cancer As shown in Table 2, univariate and multivariate Cox proportional hazards regression analyses were conducted using variables from the baseline characteristics table The results identified both the CK-MB/CK ratio and D-dimer level as independent risk factors for prognosis in this patient population. Specifically, higher levels of the CK-MB/CK ratio and D-dimer were associated with significantly worse overall survival.Table 2Univariate and Multivariate Analyses of Factors Predicting Survival in Patients with Advanced Hepatocellular Carcinoma Treated with TACEVariablesTotal (N)Univariate AnalysisMultivariate AnalysisHazard Ratio (95% CI)P valueHazard Ratio (95% CI)P valueGender158Male137ReferenceFemale211.503 (0.934–2.418)0.093Age1580.998 (0.983–1.012)0.752BMI1190.919 (0.867–0.974)0.0050.947 (0.862–1.039)0.246History of Hepatitis B158No79ReferenceYes790.778 (0.559–1.084)0.138Partial hepatectomy158No106ReferenceReferenceYes520.467 (0.323–0.673)< 0.0010.754 (0.434–1.309)0.316History of targeted therapy158No42ReferenceReferenceYes1160.623 (0.431–0.899)0.0120.692 (0.371–1.290)0.247Immunotherapy158No46ReferenceYes1121.106 (0.764–1.600)0.595China Liver Cancer Staging (CNLC)158IIIa40ReferenceIIIb941.182 (0.799–1.747)0.403IV241.362 (0.801–2.316)0.254CK-MB/CK Ratio1584.277 (2.944–6.214)< 0.0013.895 (1.946–7.796)< 0.001WBC1581.061 (1.025–1.098)< 0.0011.063 (0.756–1.493)0.727Lymphocytes1580.994 (0.813–1.215)0.954PLT1581.001 (1.000–1.003)0.118Lymphocytes1581.068 (1.030–1.108)< 0.0011.027 (0.705–1.494)0.891ALT1581.002 (1.000–1.005)0.103AST1581.001 (1.000–1.001)0.0260.997 (0.994–1.000)0.039TBIL1571.003 (1.001–1.005)0.0061.007 (0.989–1.025)0.450DBIL1571.004 (1.001–1.007)0.0140.993 (0.970–1.016)0.561APTT1551.016 (0.999–1.034)0.0600.972 (0.941–1.004)0.087PT1551.081 (1.015–1.153)0.0161.008 (0.898–1.131)0.894D-dimer1141.082 (1.041–1.124)< 0.0011.114 (1.040–1.194)0.002Notes: Data are presented as hazard ratio (HR) with 95% confidence interval (CI). Multivariate analysis was performed using the Cox proportional hazards model, incorporating variables with P < 0.05 in the univariate analysis. All laboratory parameters and the CK-MB/CK ratio were measured from pre-TACE peripheral blood samples.Abbreviations: CK-MB, creatine kinase-MB; CK, creatine kinase; WBC, white blood cell count; PLT, platelet count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; APTT, activated partial thromboplastin time; PT, prothrombin time. Table 2Univariate and Multivariate Analyses of Factors Predicting Survival in Patients with Advanced Hepatocellular Carcinoma Treated with TACEVariablesTotal (N)Univariate AnalysisMultivariate AnalysisHazard Ratio (95% CI)P valueHazard Ratio (95% CI)P valueGender158Male137ReferenceFemale211.503 (0.934–2.418)0.093Age1580.998 (0.983–1.012)0.752BMI1190.919 (0.867–0.974)0.0050.947 (0.862–1.039)0.246History of Hepatitis B158No79ReferenceYes790.778 (0.559–1.084)0.138Partial hepatectomy158No106ReferenceReferenceYes520.467 (0.323–0.673)< 0.0010.754 (0.434–1.309)0.316History of targeted therapy158No42ReferenceReferenceYes1160.623 (0.431–0.899)0.0120.692 (0.371–1.290)0.247Immunotherapy158No46ReferenceYes1121.106 (0.764–1.600)0.595China Liver Cancer Staging (CNLC)158IIIa40ReferenceIIIb941.182 (0.799–1.747)0.403IV241.362 (0.801–2.316)0.254CK-MB/CK Ratio1584.277 (2.944–6.214)< 0.0013.895 (1.946–7.796)< 0.001WBC1581.061 (1.025–1.098)< 0.0011.063 (0.756–1.493)0.727Lymphocytes1580.994 (0.813–1.215)0.954PLT1581.001 (1.000–1.003)0.118Lymphocytes1581.068 (1.030–1.108)< 0.0011.027 (0.705–1.494)0.891ALT1581.002 (1.000–1.005)0.103AST1581.001 (1.000–1.001)0.0260.997 (0.994–1.000)0.039TBIL1571.003 (1.001–1.005)0.0061.007 (0.989–1.025)0.450DBIL1571.004 (1.001–1.007)0.0140.993 (0.970–1.016)0.561APTT1551.016 (0.999–1.034)0.0600.972 (0.941–1.004)0.087PT1551.081 (1.015–1.153)0.0161.008 (0.898–1.131)0.894D-dimer1141.082 (1.041–1.124)< 0.0011.114 (1.040–1.194)0.002Notes: Data are presented as hazard ratio (HR) with 95% confidence interval (CI). Multivariate analysis was performed using the Cox proportional hazards model, incorporating variables with P < 0.05 in the univariate analysis. All laboratory parameters and the CK-MB/CK ratio were measured from pre-TACE peripheral blood samples.Abbreviations: CK-MB, creatine kinase-MB; CK, creatine kinase; WBC, white blood cell count; PLT, platelet count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; APTT, activated partial thromboplastin time; PT, prothrombin time. Univariate and Multivariate Analyses of Factors Predicting Survival in Patients with Advanced Hepatocellular Carcinoma Treated with TACE Notes: Data are presented as hazard ratio (HR) with 95% confidence interval (CI). Multivariate analysis was performed using the Cox proportional hazards model, incorporating variables with P < 0.05 in the univariate analysis. All laboratory parameters and the CK-MB/CK ratio were measured from pre-TACE peripheral blood samples. Abbreviations: CK-MB, creatine kinase-MB; CK, creatine kinase; WBC, white blood cell count; PLT, platelet count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; APTT, activated partial thromboplastin time; PT, prothrombin time. Combined Prognostic Stratification Improves Risk Discrimination To further evaluate the clinical utility of the CK-MB/CK ratio, we performed combined prognostic stratification with D-dimer and AFP, respectively. For D-dimer combination, 114 patients with available D-dimer data were stratified into four subgroups based on CK-MB/CK ratio (Normal ≤1 vs Abnormal >1) and D-dimer level (≤3.18 mg/L vs >3.18 mg/L, median cutoff). As shown in Figure 3A, Kaplan-Meier analysis revealed significant stepwise differences in overall survival across the four subgroups (log-rank P < 0.001). Patients with both abnormal CK-MB/CK ratio and high D-dimer had the worst prognosis (median OS: 19 months), with a 5.4-fold increased risk of mortality compared with the Normal+Low DD group (HR = 5.368, 95% CI: 2.840–10.148, P < 0.001).Figure 3Combined prognostic stratification by CK-MB/CK ratio with D-dimer and AFP in advanced HCC. (A)Kaplan-Meier survival curves stratified by combined CK-MB/CK ratio and D-dimer (n = 114). Four subgroups: Normal+Low DD (n = 45), Normal+High DD (n = 27), Abnormal+Low DD (n = 12), Abnormal+High DD (n = 30). Cutoffs: CK-MB/CK >1 (abnormal), D-dimer >3.18 mg/L (median). Log rank test showed significant survival differences across subgroups (P < 0.001), with the Abnormal+High DD group having the worst prognosis (HR = 5.368, 95% CI: 2.840–10.148). Tick marks indicate censored observations. (B) Kaplan-Meier survival curves stratified by combined CK-MB/CK ratio and AFP (n = 157). Four subgroups: Normal+Low AFP (n = 60), Normal+High AFP (n = 45), Abnormal+Low AFP (n = 22), Abnormal+High AFP (n = 30). Cutoffs: CK-MB/CK >1 (abnormal), AFP >400 ng/mL. Log rank test showed significant survival differences across subgroups (P < 0.001), with the Abnormal+High AFP group having the worst prognosis (HR = 10.011, 95% CI: 5.081–19.725). Tick marks indicate censored observations.Two Kaplan Meier line graphs comparing survival by CK MB over CK ratio with D dimer and AFP groups.Image A: Kaplan Meier graph with Y-axis (Survival probability, 0.00-1.00) and X-axis (Survival Time, 0-75 months). Legend: Normal+High DD (light line), Normal+Low DD (darker line), Abnormal+Low DD (dark line), Abnormal+High DD (light line). Log rank P < 0.001. Curves: Normal+Low DD highest, ends ~0.18 at 75 months; Normal+High DD lower, ends ~0.06 at 75 months; Abnormal+Low DD drops fastest, ~0.00 by 30 months; Abnormal+High DD ~0.00 by 35 months. Censor ticks on curves. Image B: Kaplan Meier graph with Y-axis (Survival probability, 0.00-1.00) and X-axis (Survival Time, 0-75 months). Legend: Normal+High AFP (light line), Normal+Low AFP (darker line), Abnormal+High AFP (dark line), Abnormal+Low AFP (light line). Log rank P < 0.001. Curves: Normal+Low AFP highest, ends ~0.15 at 75 months; Normal+High AFP lower, ends ~0.14 at 75 months; Abnormal+Low AFP ~0.05 by 60 months; Abnormal+High AFP drops fastest, ~0.00 by 30 months. Censor ticks on curves.Abbreviations: CK-MB, creatine kinase isoenzyme MB; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; HR, hazard ratio; CI, confidence interval. Combined prognostic stratification by CK-MB/CK ratio with D-dimer and AFP in advanced HCC. (A)Kaplan-Meier survival curves stratified by combined CK-MB/CK ratio and D-dimer (n = 114). Four subgroups: Normal+Low DD (n = 45), Normal+High DD (n = 27), Abnormal+Low DD (n = 12), Abnormal+High DD (n = 30). Cutoffs: CK-MB/CK >1 (abnormal), D-dimer >3.18 mg/L (median). Log rank test showed significant survival differences across subgroups (P < 0.001), with the Abnormal+High DD group having the worst prognosis (HR = 5.368, 95% CI: 2.840–10.148). Tick marks indicate censored observations. (B) Kaplan-Meier survival curves stratified by combined CK-MB/CK ratio and AFP (n = 157). Four subgroups: Normal+Low AFP (n = 60), Normal+High AFP (n = 45), Abnormal+Low AFP (n = 22), Abnormal+High AFP (n = 30). Cutoffs: CK-MB/CK >1 (abnormal), AFP >400 ng/mL. Log rank test showed significant survival differences across subgroups (P < 0.001), with the Abnormal+High AFP group having the worst prognosis (HR = 10.011, 95% CI: 5.081–19.725). Tick marks indicate censored observations. Similar results were observed for AFP combination (n = 157, cutoff: 400 ng/mL). As shown in Figure 3B, Patients with both abnormal CK-MB/CK ratio and high AFP had the poorest survival (median OS: 14 months), and combined stratification significantly improved risk discrimination compared with AFP alone (HR = 10.011, 95% CI: 5.081–19.725, P < 0.001). These findings indicate that the CK-MB/CK ratio adds incremental prognostic value to conventional biomarkers, and combined stratification enhances clinical risk assessment for advanced HCC patients undergoing TACE. Discussion Transarterial chemoembolization (TACE) is commonly used for advanced liver cancer, but patient survival is often poor. Current methods to predict outcomes are not perfect for making personalized treatment plans.17 In our study of 158 advanced liver cancer patients, we found that a higher CK-MB/CK ratio in the blood was strongly linked to worse survival. Statistical analysis confirmed it as an independent risk factor, meaning it provides unique prognostic information beyond other known factors. This easy-to-get blood test could be a useful new tool to help doctors estimate patient risk and plan better treatments. An abnormally high CK-MB/CK ratio in our cancer patients points to changes in tumor cell metabolism, not heart damage. In cancers, this can happen because tumor cells may produce CK-MB abnormally or have damaged energy factories (mitochondria).18,19 Specifically, several potential mechanisms may underlie elevated CK-MB/CK ratios in HCC: first, increased tumor burden and enhanced glycolytic metabolism can lead to muscle wasting and CK release, as cancer cells rewire energy metabolism to support rapid proliferation.20 Second, mitochondrial dysfunction in tumor cells and peritumoral tissues may contribute to abnormal CK isoenzyme expression and release.21 Third, subclinical liver injury and chronic inflammation-induced muscle breakdown can independently affect CK isoenzyme profiles, reflecting the systemic effects of advanced liver cancer.22 Studies in other cancers like colorectal cancer also found this ratio predicts poor survival, possibly because fast-growing tumor cells alter their energy use and leak enzymes.12 In pancreatic cancer, a high ratio is seen in more aggressive tumors.10 Unlike the quick rise and fall seen after a heart attack,23 the persistently high ratio in our liver cancer patients might reflect ongoing tumor cell death in a low-oxygen environment, which is a distinct feature of advanced cancer. While these mechanisms provide a plausible biological framework, we acknowledge that they remain speculative and require further experimental validation in HCC-specific models. Importantly, the elevated CK-MB/CK ratio may not solely reflect tumor-specific metabolic alterations. The lower BMI observed in the abnormal group suggests that cancer cachexia and muscle wasting may contribute to CK isoenzyme release, while elevated inflammatory markers indicate that systemic inflammation may also play a role. Although we excluded patients with clinically evident myocardial injury, subclinical muscle damage cannot be entirely ruled out. Thus, the ratio likely reflects a combination of tumor burden, muscle wasting, and systemic inflammation. Besides the CK-MB/CK ratio, our study also found that high D-dimer levels are another independent risk factor for poor survival. This connects blood clotting problems with cancer progression. High D-dimer shows the blood is more prone to clotting, a condition often seen with tumors.24,25 This can help tumor cells spread by protecting them in the bloodstream.26,27 So, both markers together highlight the link between cancer, inflammation, and abnormal blood clotting. Importantly, our combined stratification analyses demonstrated that integrating CK-MB/CK ratio with established prognostic markers such as D-dimer and AFP significantly improves risk discrimination compared with any single marker. Patients with both abnormal CK-MB/CK ratio and high D-dimer had a 5.4-fold increased risk of mortality compared with those with normal levels of both markers, and similar findings were observed for AFP combination.7,28 The synergistic prognostic effect of elevated CK-MB/CK ratio and high D-dimer suggests that both markers may reflect overlapping pathophysiological processes, including systemic inflammation and increased tumor burden. These results suggest that the CK-MB/CK ratio adds incremental prognostic value to conventional biomarkers, and combining CK-MB/CK with established prognostic scores (eg, Child-Pugh, BCLC) may further enhance personalized risk assessment for HCC patients undergoing TACE.29 The CK-MB/CK ratio was also connected to higher levels of other tumor markers (AFP, CEA, etc.) and liver damage tests (ALT, AST, Bilirubin, etc).18,30 This makes sense because as the liver tumor grows, it damages liver tissue and releases various substances into the blood. The simultaneous increase in CK-MB/CK ratio along with these markers suggests a shared underlying problem involving high tumor burden, liver failure, and potential body-wide effects.31 From a clinical perspective, our findings have several potential applications. First, the CK-MB/CK ratio can be used for preoperative risk stratification to identify high-risk patients who may benefit from more intensive surveillance or adjuvant therapy after TACE.32 Second, it may help guide TACE treatment optimization—for example, adjusting treatment frequency or considering earlier combination with systemic therapy for patients with elevated CK-MB/CK ratios.33,34 Third, as a low-cost and widely available biomarker, the CK-MB/CK ratio is particularly valuable for risk assessment in resource-limited settings where more expensive tests may not be accessible. Future studies should directly compare the prognostic performance of CK-MB/CK ratio with established HCC markers and scoring systems, such as AFP, Child-Pugh, and BCLC, to evaluate its incremental value. Our study has some limitations. First, it was a single-center, retrospective analysis with a limited number of patients (n = 158, with only 52 patients in the abnormal CK-MB/CK group), so the results might not apply to all patient groups and may be subject to selection bias despite consecutive enrollment. Second, several clinically important variables, including antiviral treatment history, alcohol consumption, and detailed cirrhosis etiology, were not systematically collected in our retrospective cohort, which may represent potential confounding factors. Third, while our sample size provides sufficient statistical power for the primary analysis, it may be inadequate for detailed subgroup analyses; future large-scale multi-center studies are needed to perform subgroup analyses stratified by age, gender, etiology, and treatment regimen. Fourth, this study only measured baseline CK-MB/CK ratio prior to TACE; dynamic monitoring of biomarker changes during follow-up was not performed, which prevents assessment of whether serial measurements correlate with treatment response or disease progression. There could also be other unknown factors affecting our findings. Additionally, the retrospective design does not allow for causal inference, and the underlying mechanisms remain speculative. Conclusion In conclusion, this exploratory retrospective study suggests that elevated preoperative CK-MB/CK ratio may serve as an independent prognostic biomarker for poor survival in advanced HCC patients undergoing TACE. The key advantage of this marker lies in its low cost and wide availability, which may facilitate risk assessment in clinical practice. Combined stratification with D-dimer further improves risk discrimination, although a formal combined risk score has not yet been developed. Future multi-center prospective studies, including comparisons with established prognostic systems such as BCLC and Child-Pugh classifications, and in vitro/in vivo mechanistic investigations are warranted to validate these findings and elucidate the underlying biological pathways before clinical application.